NO328693B1 - Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH. - Google Patents
Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH. Download PDFInfo
- Publication number
- NO328693B1 NO328693B1 NO20023963A NO20023963A NO328693B1 NO 328693 B1 NO328693 B1 NO 328693B1 NO 20023963 A NO20023963 A NO 20023963A NO 20023963 A NO20023963 A NO 20023963A NO 328693 B1 NO328693 B1 NO 328693B1
- Authority
- NO
- Norway
- Prior art keywords
- recombinant
- phase hplc
- column
- exchange chromatography
- sample
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title claims description 4
- 230000000694 effects Effects 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 28
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 24
- 238000000746 purification Methods 0.000 claims abstract description 22
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 63
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 17
- 239000005695 Ammonium acetate Substances 0.000 claims description 17
- 229940043376 ammonium acetate Drugs 0.000 claims description 17
- 235000019257 ammonium acetate Nutrition 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 13
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000377 silicon dioxide Substances 0.000 claims description 7
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 6
- 239000012614 Q-Sepharose Substances 0.000 claims description 5
- 230000004071 biological effect Effects 0.000 claims description 5
- 239000003957 anion exchange resin Substances 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 208000021267 infertility disease Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract description 57
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract description 57
- 229940040129 luteinizing hormone Drugs 0.000 abstract description 57
- 230000008569 process Effects 0.000 abstract description 15
- 239000000356 contaminant Substances 0.000 abstract description 10
- 239000006228 supernatant Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000108 ultra-filtration Methods 0.000 description 12
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 11
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 11
- 229940028334 follicle stimulating hormone Drugs 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 8
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
- 239000001099 ammonium carbonate Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000012465 retentate Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 239000012506 Sephacryl® Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000005342 ion exchange Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 102000006771 Gonadotropins Human genes 0.000 description 4
- 108010086677 Gonadotropins Proteins 0.000 description 4
- 108010057021 Menotropins Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 239000002622 gonadotropin Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000001592 luteinising effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000208140 Acer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- -1 anionic oligosaccharides Chemical class 0.000 description 1
- NOJOIAIHUITBDB-UHFFFAOYSA-N azanium;propan-2-ol;acetate Chemical compound [NH4+].CC(C)O.CC([O-])=O NOJOIAIHUITBDB-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000002086 displacement chromatography Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003204 ejaculatory duct Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Semiconductor Lasers (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00103692 | 2000-02-22 | ||
| PCT/EP2001/000666 WO2001062774A2 (en) | 2000-02-22 | 2001-01-22 | Purified lh |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023963D0 NO20023963D0 (no) | 2002-08-20 |
| NO20023963L NO20023963L (no) | 2002-08-20 |
| NO328693B1 true NO328693B1 (no) | 2010-04-26 |
Family
ID=8167926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023963A NO328693B1 (no) | 2000-02-22 | 2002-08-20 | Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7053054B2 (cs) |
| EP (2) | EP1777231A3 (cs) |
| JP (1) | JP4959898B2 (cs) |
| KR (1) | KR100808149B1 (cs) |
| CN (1) | CN100480258C (cs) |
| AT (1) | ATE356138T1 (cs) |
| AU (1) | AU780377B2 (cs) |
| BG (1) | BG65761B1 (cs) |
| BR (2) | BR122012018280B8 (cs) |
| CA (1) | CA2399100C (cs) |
| CY (1) | CY1108056T1 (cs) |
| CZ (1) | CZ303274B6 (cs) |
| DE (1) | DE60127100T2 (cs) |
| DK (1) | DK1261622T3 (cs) |
| EA (1) | EA004385B1 (cs) |
| EE (1) | EE04932B1 (cs) |
| ES (1) | ES2278722T3 (cs) |
| HR (1) | HRP20020651B1 (cs) |
| HU (1) | HU227007B1 (cs) |
| IL (2) | IL151309A0 (cs) |
| MX (1) | MXPA02007867A (cs) |
| NO (1) | NO328693B1 (cs) |
| PL (1) | PL207728B1 (cs) |
| PT (1) | PT1261622E (cs) |
| RS (1) | RS50416B (cs) |
| SI (1) | SI1261622T1 (cs) |
| SK (1) | SK287041B6 (cs) |
| UA (2) | UA78676C2 (cs) |
| WO (1) | WO2001062774A2 (cs) |
| ZA (1) | ZA200206108B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE356138T1 (de) * | 2000-02-22 | 2007-03-15 | Applied Research Systems | Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung |
| DE10235168A1 (de) * | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| US10105417B2 (en) | 2003-03-04 | 2018-10-23 | Aspenbio Pharma, Inc. | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
| CN1283792C (zh) * | 2003-11-14 | 2006-11-08 | 余伟明 | 生物大分子组分相分离法 |
| DE602004023757D1 (de) * | 2003-12-22 | 2009-12-03 | Ares Trading Sa | Methode zur reinigung von fsh |
| WO2006041945A2 (en) * | 2004-10-04 | 2006-04-20 | Novetide, Ltd. | A counterion exchange process for peptides |
| HRP20080464T3 (en) * | 2004-11-09 | 2008-10-31 | Ares Trading S.A. | Method for purifying fsh |
| AU2005335900B2 (en) * | 2005-08-26 | 2012-03-29 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
| CA2625978A1 (en) | 2005-12-09 | 2007-06-14 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
| CA2702448A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying fc-fusion proteins |
| US20100256337A1 (en) * | 2007-10-22 | 2010-10-07 | Merck Serono Sa | Method for purifying an fc-containing protein |
| CN101928342B (zh) * | 2009-06-18 | 2013-05-08 | 上海天伟生物制药有限公司 | 一种高纯度绝经期促性腺素及其制备方法和用途 |
| US10400019B2 (en) * | 2014-05-01 | 2019-09-03 | Virginia Tech Intellectual Properties, Inc. | Keratin nanomaterials and methods of production |
| CN104569441B (zh) * | 2015-01-19 | 2016-02-03 | 成都大熊猫繁育研究基地 | 大熊猫尿液促黄体素的酶联检测方法及其应用 |
| EP3969026A1 (en) | 2019-05-16 | 2022-03-23 | Ceva Santé Animale | Compositions and methods for increasing reproduction performance in non human mammals using recombinant luteinizing hormone |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002757A1 (en) * | 1988-09-02 | 1990-03-22 | Integrated Genetics, Inc. | Heteropolymeric protein |
| DE69029799T2 (de) * | 1989-02-21 | 1997-05-28 | Washington University, St. Louis, Mo. | Modifizierte formen von fortpflanzungshormonen |
| US5087615A (en) * | 1989-03-17 | 1992-02-11 | Applied Research Systems Ars Holding N.V. | Novel method of ovulation induction in humans |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| IT1287138B1 (it) * | 1996-11-07 | 1998-08-04 | Ibsa Inst Biochimique Sa | Procedimento per la separazione e purificazione di fsh e lh |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| CA2293731C (en) * | 1997-06-25 | 2010-01-12 | Applied Research Systems Ars Holding N.V. | Disulfide cross-linking glycoprotein hormone analogs, and their preparation and use |
| ATE356138T1 (de) * | 2000-02-22 | 2007-03-15 | Applied Research Systems | Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung |
-
2001
- 2001-01-22 AT AT01907476T patent/ATE356138T1/de active
- 2001-01-22 HR HR20020651A patent/HRP20020651B1/xx not_active IP Right Cessation
- 2001-01-22 JP JP2001562555A patent/JP4959898B2/ja not_active Expired - Lifetime
- 2001-01-22 KR KR1020027010624A patent/KR100808149B1/ko not_active Expired - Lifetime
- 2001-01-22 EP EP06016629A patent/EP1777231A3/en not_active Withdrawn
- 2001-01-22 MX MXPA02007867A patent/MXPA02007867A/es active IP Right Grant
- 2001-01-22 SK SK1205-2002A patent/SK287041B6/sk not_active IP Right Cessation
- 2001-01-22 DK DK01907476T patent/DK1261622T3/da active
- 2001-01-22 CA CA2399100A patent/CA2399100C/en not_active Expired - Fee Related
- 2001-01-22 EA EA200200893A patent/EA004385B1/ru not_active IP Right Cessation
- 2001-01-22 CZ CZ20022856A patent/CZ303274B6/cs not_active IP Right Cessation
- 2001-01-22 SI SI200130709T patent/SI1261622T1/sl unknown
- 2001-01-22 CN CNB018053645A patent/CN100480258C/zh not_active Expired - Lifetime
- 2001-01-22 HU HU0301814A patent/HU227007B1/hu unknown
- 2001-01-22 WO PCT/EP2001/000666 patent/WO2001062774A2/en active IP Right Grant
- 2001-01-22 IL IL15130901A patent/IL151309A0/xx unknown
- 2001-01-22 DE DE60127100T patent/DE60127100T2/de not_active Expired - Lifetime
- 2001-01-22 PL PL362891A patent/PL207728B1/pl unknown
- 2001-01-22 BR BR122012018280A patent/BR122012018280B8/pt not_active IP Right Cessation
- 2001-01-22 UA UA2002086889A patent/UA78676C2/xx unknown
- 2001-01-22 EE EEP200200464A patent/EE04932B1/xx unknown
- 2001-01-22 UA UAA200612399A patent/UA92145C2/uk unknown
- 2001-01-22 EP EP01907476A patent/EP1261622B1/en not_active Expired - Lifetime
- 2001-01-22 US US10/204,554 patent/US7053054B2/en not_active Expired - Lifetime
- 2001-01-22 ES ES01907476T patent/ES2278722T3/es not_active Expired - Lifetime
- 2001-01-22 RS YUP-603/02A patent/RS50416B/sr unknown
- 2001-01-22 AU AU35436/01A patent/AU780377B2/en not_active Expired
- 2001-01-22 BR BRPI0108553A patent/BRPI0108553B8/pt not_active IP Right Cessation
- 2001-01-22 PT PT01907476T patent/PT1261622E/pt unknown
-
2002
- 2002-07-31 ZA ZA200206108A patent/ZA200206108B/en unknown
- 2002-08-14 BG BG107001A patent/BG65761B1/bg unknown
- 2002-08-18 IL IL151309A patent/IL151309A/en active IP Right Grant
- 2002-08-20 NO NO20023963A patent/NO328693B1/no not_active IP Right Cessation
-
2005
- 2005-11-28 US US11/287,341 patent/US20060079460A1/en not_active Abandoned
-
2007
- 2007-05-10 CY CY20071100638T patent/CY1108056T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328693B1 (no) | Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH. | |
| AU2006200059A1 (en) | Process of purification of HCG and recombinant HCG purified by that method | |
| HK1052014B (en) | Purified lh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| MK1K | Patent expired |